
Product Data Sheet

Product Name: S-MTC
Cat. No.: GC31243

Chemical Properties

Cas. No. 156719-41-4

SMILES N[C@@H](CCCNC(SC)=N)C(O)=O

Formula $C_7H_{15}N_3O_2S$ M.Wt 205.28

Solubility Soluble in DMSO Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Protocol

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

**Cell
experiment:**

Mixed cortical glial and neuronal cultured cells are prepared from E15 to E18 embryos obtained from Spargue-Dawley rats. On day 7 after plating, the culture medium is removed and replaced with freshly prepared culture medium in the presence of either A β 1-42 (1, 5, 10, or 20 μ M), A β 42-1, or peroxy-nitrite (100 or 200 μ M) with or without either NG-nitro-L-arginine (L-NOARG, 10 or 100 μ M), S-MTC (10 or 100 μ M), N-iminoethyl-L-lysine (10 or 100 μ M), N-(3-(aminomethyl)benzyl)acetamide (1400W, 1 or 5 μ M), 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazole-1-oxyl-3-oxide (carboxy-PTIO, 10 or 100 μ M), or 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (10 or 100 μ M) alone or in combination. The cultured cells are then incubated for 20 h. For the time-course studies, the cultured cells are pre-treated with the described culture medium containing A β 1-42 (10 μ M). Either L-NIL (100 μ M), L-NOARG (100 μ M), 1400W (5 μ M), S-MTC (100 μ M), carboxy-PTIO (100 μ M) or Trolox (100 μ M) are administered at 1, 4, and 8 h later. Assessments are carried out 20 h after A β 1-42 administration. The viability of cultured cells is evaluated by using MTT and neutral red colorimetric assays. MTT reduction and NR uptake are quantified at 570 and 540 nm, respectively, by using a micro-plate reader[1].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Animal experiment:

mice[2] Male NIH Swiss mice, weighing 18-22 g, are used. S-MTC (1.0 µg/mouse) is administered i.c.v. (15-min pretreatment time). In one set of experiments (#1, #2, and #3), opioid antagonists and NOS-inhibitors are administered 15-30 min prior to the 60-min HBO2 treatment (180 min prior to antinociceptive testing). In another experiment (#4), opioid antagonist and NOS-inhibitor pretreatment is administered 60 min following cessation of the 60-min HBO2 treatment (15-30 min prior to antinociceptive testing). For i.p. or s.c. pretreatments, the volume of injection is 0.1 mL/10 g body weight with control animals receiving an i.p. or s.c. injection of vehicle (sterile saline) only. For i.c.v. pretreatments, the volume of microinjection is 5.0 µL per mouse with control animals receiving an i.c.v. microinjection of vehicle (sterile saline) only.

Rats[3] Male, Sprague-Dawley rats (350-450 g) are used. On the day after catheterisation (day 1), animals (n=7) receive bolus i.v. injections (0.1 mL) of either saline (vehicle), and 0.3 and 3 mg/kg S-MTC (n=4), or 0.1, 1 and 10 mg/kg S-MTC (n=3). On day 3, the dose regimen is switched to ensure that each animal has received all the doses of S-MTC. On each day, drugs are given in ascending dose-order, and at least 60 min is allowed between doses. The intervening day (day 2) is allowed for wash-out of any drug effects.

References:

[1]. Law A, et al.
Neuroprotective
and
neurorescuing
effects of
isoform-specific
nitric oxide
synthase
inhibitors, nitric
oxide scavenger,

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

and antioxidant
against beta-
amyloid toxicity.
Br J Pharmacol.
2001
Aug;133(7):1114-
24.
[2]. Zelinski LM,
et al. A
prolonged nitric
oxide-dependent,
opioid-mediated
antinociceptive
effect of
hyperbaric
oxygen in mice. J
Pain. 2009
Feb;10(2):167-
72.
[3]. Wakefield ID,
et al.
Comparative
regional
haemodynamic
effects of the
nitric oxide
synthase
inhibitors, S-
methyl-L-
thiocitrulline and
L-NAME, in
conscious rats. Br
J Pharmacol.
2003
Jul;139(6):1235-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

43.

Background

S-MTC is a selective type I nitric oxide synthase (NOS) inhibitor.

S-MTC (10 or 100 μM) reduces cellular NO release in the absence of A β 1-42. At 100 μM , S-MTC decreases cell viability. S-MTC (100 μM) significantly lowers nitrite production (11.2 ± 1.1 μM) when compared to control (no NOS inhibitor exposure; 19.6 ± 1.2 μM). Nitrite productions after A β 1-42 and L-NOARG (100 μM) or A β 1-42 and S-MTC (100 μM) treatments are significantly lower than A β 1-42 alone (33.5 ± 2.0 and 34.5 ± 1.6 μM , respectively). S-MTC (100 μM) is able to significantly reduce nitrite production (25.2 ± 1.1 μM) as compared to A β 1-42 treatment alone (38.3 ± 2.7 μM), when administered after A β 1-42 at the 1 h time point. S-MTC (100 μM) concentration decreases both MTT ($87\pm 1\%$ of control) and NR ($80\pm 1\%$ of control, respectively) levels. The co-administration of S-MTC (100 μM) and A β 1-42 significantly reverses the effects of A β 1-42 alone ($72\pm 2\%$ vs $61\pm 2\%$ of control)[1].

S-MTC (S-methyl-L-thiocitrulline) is a selective neuronal NOS-inhibitor. Following pretreatment with S-MTC (i.c.v.), the HBO₂-induced antinociception is significantly antagonized. In Experiment #2, different groups of mice are pretreated with naltrexone hydrochloride (NTX) (3.0 mg/kg, i.p.), L-NAME (1.0 μg /mouse, i.c.v.), S-MTC (1.0 μg /mouse, i.c.v.) or N⁵-(1-iminoethyl)-L-ornithine (L-NIO) (3.0 mg/kg, s.c.) 15-30 min prior to HBO₂ treatment. The antinociceptive effect assessed 90 min after HBO₂ treatment is completely abolished by NTX and L-NAME, antagonized by two-thirds by S-MTC and largely unaffected by L-NIO ($F=25.57$, p

[1]. Law A, et al. Neuroprotective and neurorescuing effects of isoform-specific nitric oxide synthase inhibitors, nitric oxide scavenger, and antioxidant against beta-amyloid toxicity. Br J Pharmacol. 2001 Aug;133(7):1114-24. [2]. Zelinski LM, et al. A prolonged nitric oxide-dependent, opioid-mediated antinociceptive effect of hyperbaric oxygen in mice. J Pain. 2009 Feb;10(2):167-72. [3]. Wakefield ID, et al. Comparative regional haemodynamic effects of the nitric oxide synthase inhibitors, S-methyl-L-thiocitrulline and L-NAME, in conscious rats. Br J Pharmacol. 2003 Jul;139(6):1235-43.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA